DIL Dyadic International

Dyadic International, Inc. (AMEX: DIL), a biotechnology company engaged in the development, manufacture and sale of biological products, today announced that its President and CEO, Mark Emalfarb, will present at the Roth Capital Partners New York Conference to be held on September 7-8, 2005, at the Westin New York at Times Square. Dyadic's investor presentation is scheduled for Thursday, September 8th at 9:00 a.m. EDT. The presentation will be webcast live and archived online for 30 days on the Investor Relations section of the company's website at www.dyadic-group.com . About Dyadic Dyadic International, Inc., is engaged in the development, manufacture and sale of biological products (proteins, enzymes, peptides and other bio-molecules), as well as the licensing of its enabling proprietary technology to business collaborators for the discovery, development and manufacture of biological products from genes. Dyadic markets its products and services for applications in the textile, chemical, agricultural, pulp & paper, pharmaceutical, biotechnology and other industries, using its proprietary C1 Host Technology and C1 Expression and Screening Systems for the discovery, development and production of biological products. Cautionary Statement for Forward-Looking Statements Statements contained in this press release may contain information that includes or is based upon certain "forward-looking statements" relating to our business. For a discussion of the factors that could cause actual results to vary from these forward-looking statements, please see our filings from time to time with the Securities and Exchange Commission, which are available free of charge on the SEC's web site at http://www.sec.gov, including our Annual Report on Form 10-KSB for the year ended December 31, 2004, which was filed with the SEC on April 15, 2005, and our Quarterly Report for the quarter ended June 30, 2005 on Form 10-QSB, which was filed on August 15, 2005. Except as required by law, we expressly disclaim any intent or obligation to update any forward-looking statements.